Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data ...
(ETNB), highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in our Phase 3 ENTRUST trial in SHTG,” stated Rohan Palekar, ...
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
89bio's pegozafermin, an FGF21 analog, is currently being evaluated in three Phase III trials. Two of these trials are focused on different MASH populations, while the third targets SHTG patients.
UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...
89bio (NASDAQ:ETNB – Get Free Report) had its price target boosted by stock analysts at UBS Group from $25.00 to $38.00 in a research note issued on Friday,Benzinga reports.The brokerage ...
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB's 50-day simple moving average crossed above its 200 ...
Check Out Our Latest Report on 89bio 89bio Price Performance Shares of ETNB opened at $11.43 on Wednesday. The business’s 50 day moving average price is $7.94 and its two-hundred day moving ...
89bio's main value driver is Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. Management mentioned we should get its SHTG topline data by 2H2025. This could be a ...
89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...